SLDB Solid Biosciences Inc.
Financings ·
Solid Biosciences filed a prospectus supplement for up to $200,000,000 of at-the-market stock sales through Jefferies, replacing a prior $85,000,000 program. The filing says buyers would face dilution of about $4.30 per share at an assumed $8.73 price.
Solid Biosciences stockholders voted at the June 10, 2026 annual meeting to double authorized common stock to 480,000,000 shares. The vote drew 893,360 votes against, and the say-on-pay vote drew 6,203,634 against.
Solid Biosciences filed a prospectus supplement on June 5, 2026 that adds holders who bought shares from existing selling stockholders. Several holders in the table are offering their entire stake, and the company says it does not know when or in what amounts they will sell.
Solid Biosciences agreed to sell 14,973,257 shares at $5.61 and pre-funded warrants for 27,807,482 shares, for about $240.0 million gross. Its year-end 2025 cash figure is a preliminary, unaudited estimate, and the company says the deal extends runway into the first half of 2028.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $140.3 million | $96.4 million |
| Cash from operations | -$156.3 million | -$100.0 million |
| Cash and equivalents | $59.9 million | $80.2 million |
| Short-term investments | $128.0 million | $68.7 million |
Our latest story on this, dated Aug 6, 2026: "Solid Biosciences adds sales program of up to $200,000,000 with Jefferies". The story links the filing or release it is based on. Read the story.
Solid Biosciences Inc. trades under the ticker SLDB on NASDAQ.
Solid Biosciences Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Solid Biosciences Inc. is 1707502. Its filings are on SEC EDGAR.
107,225,238 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Solid Biosciences Inc. under United States.
Our directory classifies Solid Biosciences Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Solid Biosciences Inc. is US83422E2046.
aibio.space lists Solid Biosciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$140.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$377.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Solid Biosciences, dated Aug 6, 2026: "Solid Biosciences adds sales program of up to $200,000,000 with Jefferies". Solid Biosciences filed a prospectus supplement for up to $200,000,000 of at-the-market stock sales through Jefferies, replacing a prior $85,000,000 program. The filing says buyers would face dilution of about $4.30 per share at an assumed $8.73 price. Source.
From our story of Mar 6, 2026: The company estimates that the net proceeds, together with its existing cash and securities, will fund its operating expenses and capital expenditure requirements into the first half of 2028. Source.
Our latest listing story, dated Jun 10, 2026: "Solid Biosciences holders approve doubling authorized shares to 480,000,000". Solid Biosciences stockholders voted at the June 10, 2026 annual meeting to double authorized common stock to 480,000,000 shares. The vote drew 893,360 votes against, and the say-on-pay vote drew 6,203,634 against. Source.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Filed a final prospectus for a securities offering. SEC Form 424B7. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio